ES2188750T3 - Procedimiento para la preparacion de particulas respirables. - Google Patents

Procedimiento para la preparacion de particulas respirables.

Info

Publication number
ES2188750T3
ES2188750T3 ES96910285T ES96910285T ES2188750T3 ES 2188750 T3 ES2188750 T3 ES 2188750T3 ES 96910285 T ES96910285 T ES 96910285T ES 96910285 T ES96910285 T ES 96910285T ES 2188750 T3 ES2188750 T3 ES 2188750T3
Authority
ES
Spain
Prior art keywords
procedure
preparation
inhalation
solvent
breathable particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96910285T
Other languages
English (en)
Inventor
Edib Jakupovic
Jan Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20397958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2188750(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2188750T3 publication Critical patent/ES2188750T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Abstract

UN PROCESO PARA PRODUCIR UN POLVO FARMACEUTICO PARA INHALACION QUE COMPRENDE PARTICULAS CRISTALINAS DE UN COMPUESTO PARA INHALACION, QUE COMPRENDE DISOLVER UN COMPUESTO DE INHALACION EN UN SOLVENTE; E INTRODUCIR LA SOLUCION QUE CONTIENE EL COMPUESTO DE INHALACION EN FORMA DE GOTICULAS O COMO UN CHORRO EN UN ANTISOLVENTE QUE ES MISCIBLE CON EL SOLVENTE Y QUE SE ENCUENTRA EN AGITACION.
ES96910285T 1995-04-13 1996-04-12 Procedimiento para la preparacion de particulas respirables. Expired - Lifetime ES2188750T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501384A SE9501384D0 (sv) 1995-04-13 1995-04-13 Process for the preparation of respirable particles

Publications (1)

Publication Number Publication Date
ES2188750T3 true ES2188750T3 (es) 2003-07-01

Family

ID=20397958

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96910285T Expired - Lifetime ES2188750T3 (es) 1995-04-13 1996-04-12 Procedimiento para la preparacion de particulas respirables.

Country Status (22)

Country Link
US (1) US6221398B1 (es)
EP (1) EP0820276B1 (es)
JP (1) JPH11503448A (es)
CN (1) CN1102383C (es)
AR (1) AR001624A1 (es)
AT (1) ATE230257T1 (es)
AU (1) AU694863B2 (es)
CA (1) CA2217062A1 (es)
DE (1) DE69625589T2 (es)
DK (1) DK0820276T3 (es)
ES (1) ES2188750T3 (es)
IL (1) IL117841A (es)
IN (1) IN185119B (es)
MY (1) MY117344A (es)
NO (1) NO316209B1 (es)
NZ (1) NZ305515A (es)
PT (1) PT820276E (es)
SA (1) SA96160645B1 (es)
SE (1) SE9501384D0 (es)
TW (1) TW492877B (es)
WO (1) WO1996032095A1 (es)
ZA (1) ZA962596B (es)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
SE9701956D0 (sv) 1997-05-23 1997-05-23 Astra Ab New composition of matter
JP2002510310A (ja) * 1997-06-27 2002-04-02 アストラ・アクチエボラーグ 抗喘息薬の新規配合
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
GB9806477D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved crystals
GB2341120B (en) 1998-09-04 2002-04-17 Aea Technology Plc Controlling uniformity of crystalline precipitates
SE9803770D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
SE9804001D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New process
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
GB9905512D0 (en) * 1999-03-10 1999-05-05 Smithkline Beecham Plc Process
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
TWI236930B (en) 2000-05-26 2005-08-01 Pfizer Prod Inc Reactive crystallization method to improve particle size
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
EP1409101B1 (en) 2001-05-05 2006-04-12 Accentus plc Formation of small crystals
DE10137017A1 (de) * 2001-07-30 2003-02-20 Basf Ag Kristallisationsverfahren zur Einstellung kleiner Partikel
WO2003032951A1 (en) * 2001-08-29 2003-04-24 Dow Global Technologies Inc. A process for preparing crystalline drug particles by means of precipitation
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
MXPA04002446A (es) * 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
WO2003070285A1 (en) * 2002-02-19 2003-08-28 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
DE10214031A1 (de) * 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
FI20020857A (fi) * 2002-05-07 2003-11-08 Focus Inhalation Oy Amorfisen aineen muuntaminen vastaavaksi kiteiseksi aineeksi spraykuivaamalla ja käyttämällä kiteistä spraykuivattua ainetta lääkevalmisteissa
LT1531794T (lt) * 2002-06-28 2017-08-25 Civitas Therapeutics, Inc. Inhaliuojamas epinefrinas
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040028746A1 (en) * 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004066912A2 (en) * 2003-01-31 2004-08-12 Technion Research & Development Foundation Ltd. Anti-inflammatory compositions and uses thereof
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP5154078B2 (ja) * 2003-02-21 2013-02-27 ザ ユニヴァーシティ オブ バース 粒子の製造プロセス
US7041144B2 (en) * 2003-03-04 2006-05-09 Five Star Technologies, Inc. Hydrodynamic cavitation crystallization process
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
CA2523883C (en) * 2003-04-29 2012-01-03 Akzo Nobel N.V. Antisolvent solidification process
EP1683560A4 (en) * 2003-06-10 2008-10-01 Taisho Pharmaceutical Co Ltd RADIAL SPHERICAL CRYSTALLIZATION PRODUCT, PROCESS FOR PRODUCING THE CRYSTALLIZATION AND PREPARATION OF DRY POWDER CONTAINING THE CRYSTALLIZATION PRODUCT
SE0302029D0 (sv) * 2003-07-07 2003-07-07 Astrazeneca Ab Novel process
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US20070231398A1 (en) * 2004-05-05 2007-10-04 Van Lare Cornelis E J Antisolvent Emulsion Solidification Process
US7968575B2 (en) * 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1753734A1 (en) * 2004-05-05 2007-02-21 Renopharm Ltd. Nitric oxide donors and uses thereof
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
WO2006045795A2 (en) * 2004-10-29 2006-05-04 Akzo Nobel N.V. Processes involving the use of antisolvent crystallization
US20060120972A1 (en) * 2004-11-09 2006-06-08 Peter Engels 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
WO2006096906A1 (en) * 2005-03-18 2006-09-21 Nanomaterials Technology Pte Ltd Inhalable drug
WO2006113309A1 (en) 2005-04-15 2006-10-26 Dr. Reddy's Laboratories Ltd. Lacidipine particles
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
WO2007011989A2 (en) * 2005-07-15 2007-01-25 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
US8475845B2 (en) * 2005-07-15 2013-07-02 Map Pharmaceuticals, Inc. Method of particle formation
US10532028B2 (en) * 2005-07-28 2020-01-14 Isp Investments Llc Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
CN101309669A (zh) * 2005-11-15 2008-11-19 巴克斯特国际公司 脂氧合酶抑制剂的组合物
EP1978933A2 (en) * 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
WO2007070851A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008057048A1 (en) * 2006-11-09 2008-05-15 Nanomaterials Technology Pte Ltd Nano & micro-sized particles of statin compounds and process for forming same
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
WO2008092057A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Formulation process method to produce spray dried products
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP2191821A1 (en) * 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
US8236862B2 (en) * 2009-02-06 2012-08-07 University Of Southern California Therapeutic compositions comprising monoterpenes
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
SG178036A1 (en) 2009-07-15 2012-03-29 Theravance Inc Crystalline freebase forms of a biphenyl compound
US20110229437A1 (en) * 2009-09-17 2011-09-22 Mutual Pharmaceutical Company, Inc. Method of Treating Asthma with Antiviral Agents
UA118087C2 (uk) * 2009-10-01 2018-11-26 Адер Фармасьютікалз, Інк. Композиція кортикостероїду, застосована перорально
CA3023725C (en) 2009-10-22 2021-09-14 Vizuri Health Sciences Llc Methods of producing hydrated flavonoids and use thereof in the preparation of topical compositions
CA2828833C (en) 2010-03-03 2020-11-03 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
CN101849910B (zh) * 2010-05-18 2012-02-22 重庆华邦制药股份有限公司 一种二丙酸倍他米松微粒的制备方法
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
BR112013004698B1 (pt) 2010-08-27 2022-03-22 Neonc Technologies Inc. Composições farmacêuticas compreendendo derivados de poh
CA2812262A1 (en) 2010-09-22 2012-03-29 Map Pharmaceuticals, Inc. Aerosol composition for administering drugs
CN103517892B (zh) 2010-12-17 2016-01-27 尼昂克技术公司 使用异紫苏醇的方法和装置
CN102134236B (zh) * 2011-04-15 2013-07-24 北方民族大学 微细克拉霉素粉体的制备方法
AU2012282936B2 (en) * 2011-07-08 2016-11-10 Pfizer Limited Process for the preparation of fluticasone propionate form 1
CN103874483B (zh) 2011-10-11 2017-09-12 奇斯药制品公司 包衣了脂肪酸的β‑激动剂的晶体微粒
DE102012221219B4 (de) * 2012-11-20 2014-05-28 Jesalis Pharma Gmbh Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel
CN105142638B (zh) 2013-03-15 2020-08-28 维罗纳制药公司 药物组合
SI3142701T1 (en) 2014-05-12 2018-08-31 Verona Pharma Plc NEW TREATMENT
DK3166595T3 (da) * 2014-07-08 2019-08-05 Amphastar Pharmaceuticals Inc Mikroniseret insulin, mikroniserede insulinanaloger, og fremgangsmåder til fremstilling deraf
CN107613768B (zh) 2015-02-12 2020-10-20 NeOnc技术股份有限公司 包含紫苏醇衍生物的药物组合物
US10322168B2 (en) 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
EP3547836A4 (en) 2016-11-30 2020-08-05 Neonc Technologies Inc. PERILLYL ALCOHOL-3 BROMOPYRUVATE CONJUGATE AND METHOD OF TREATMENT OF CANCER
BR112020016074A2 (pt) 2018-02-08 2020-12-08 Neonc Technologies, Inc Métodos de permeabilização da barreira hematoencefálica
US20210369667A1 (en) 2019-03-29 2021-12-02 Vizuri Health Sciences Consumer Healthcare, Inc. Compositions and methods for the prevention and treatment of radiation dermatitis, eczema, burns, wounds and certain cancers
CN114262316A (zh) * 2021-12-24 2022-04-01 嘉应学院 纳米橙皮素、其制备方法及所用双匀浆空化射流系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
JP2843857B2 (ja) * 1988-10-05 1999-01-06 ファルマシア・アンド・アップジョン・カンパニー 反溶剤への沈澱を介する微細分化固体結晶性粉末
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
IE67187B1 (en) * 1990-06-15 1996-03-06 Merck & Co Inc A crystallization method to improve crystal structure and size
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles

Also Published As

Publication number Publication date
SE9501384D0 (sv) 1995-04-13
IL117841A (en) 2004-01-04
TW492877B (en) 2002-07-01
CN1102383C (zh) 2003-03-05
MY117344A (en) 2004-06-30
NO974557L (no) 1997-10-02
EP0820276A1 (en) 1998-01-28
IL117841A0 (en) 1996-08-04
IN185119B (es) 2000-11-18
JPH11503448A (ja) 1999-03-26
PT820276E (pt) 2003-04-30
DE69625589T2 (de) 2003-09-25
WO1996032095A1 (en) 1996-10-17
NZ305515A (en) 1999-03-29
NO316209B1 (no) 2003-12-29
DK0820276T3 (da) 2003-03-17
NO974557D0 (no) 1997-10-02
AU694863B2 (en) 1998-07-30
ATE230257T1 (de) 2003-01-15
CN1186428A (zh) 1998-07-01
EP0820276B1 (en) 2003-01-02
DE69625589D1 (de) 2003-02-06
ZA962596B (en) 1996-10-14
CA2217062A1 (en) 1996-10-17
US6221398B1 (en) 2001-04-24
SA96160645B1 (ar) 2005-07-05
AR001624A1 (es) 1997-11-26
AU5352496A (en) 1996-10-30

Similar Documents

Publication Publication Date Title
ES2188750T3 (es) Procedimiento para la preparacion de particulas respirables.
AR002614A1 (es) Nuevo preparado medicamentoso estable para la produccion de aerosoles exentos de gas propulsor
DE3481170D1 (de) Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung.
AR003455A1 (es) Derivados tetraciclicos, su uso en la preparacion de un medicamento, un metodo de tratamiento, una composicion farmaceutica y procesos para lapreparacion de una composicion farmaceutica y para preparar los compuestos.
ES2052829T3 (es) Aminoetiltetralinas substituidas asi como sus analogos heterociclicos.
AR018440A1 (es) Composicion de compuestos de boroprolina ciclico, metodo para la fabricacion de dicha composicion farmaceutica, metodo para estimular la activacion o laproliferacion de linfocitos o celulas hematopoyeticas humanas, y uso de dichos compuestos para preparar un medicamento util para estimular la activa
NO174877C (no) Fremgangsmåte for fremstilling av et legemiddel med antitumorvirkning
ES2193578T3 (es) Complejos de calcio para el enriquecimiento de alimentos.
FI103791B1 (fi) Menetelmä ja välituote uusien D-vitamiinianalogien valmistamiseksi
AR019365A1 (es) Compuesto de 1-piperidin-3-fenil-butil-naftamida, proceso para prepararlo, composicion farmaceutica y uso para fabricar un medicamento util para eltratamiento de una enfermedad por antagonistas de taquicininas neuropeptidicas endogenas
DE69920945D1 (de) Verfahren zur herstellung von arzneistoffpartikeln
AR018357A1 (es) Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
ZA953358B (en) New pharmaceutical composition based on taxoids
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
PT81966B (pt) Processo para a preparacao de liposomas, de composicoes apropriadas para a obtensao de uma pluralidade de doses unitarias que os contem, e embalagens para a sua utilizacao
ES2174054T3 (es) Composiciones farmaceuticas acuosas liquidas que comprenden alginato sodico y bicarbonato potasico.
EA200100540A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину
ES2101334T3 (es) Utilizacion terapeutica de la fosforil-l-serina-n-acil-esfingosina.
AR003434A1 (es) Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas.
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico
AR004165A1 (es) Una sal de diclavulanato de bis-(2-dialquilaminoalquil)-eter; un procedimiento para preparar la misma; y una composicion farmaceutica que la contiene
NO975923D0 (no) Fremgangsmåte for fremstilling av aktive stoffer fra ubrukte eller avhendede innretninger for transdermal administering av aktive stoffer og/eller fra deres produksjonsavfall
ES2196595T3 (es) Polihidroxibutilpirazinas, su preparacion y medicantes que los contienen.
DK0865422T3 (da) Anvendelse af aminoalkoholderivater som lægemidler, hidtil ukendte derivater og fremgangsmåde til fremstilling deraf
UY26381A1 (es) Derivados de ter-butil-(7-metil-imidazo 1.2-a piridin-3-il)-amina. procedimiento para su preparacion, medicamentos que los contienen, su uso para la preparacion de un medicamento para la inhibicion de no-sintasa y composiciones farmaceuticas que los